drugset / Trial / NCT00000143

Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)

NCT00000143

Phase 3 Completed 61 enrolled Johns Hopkins Bloomberg School of Public Health
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir intraocular device plus oral ganciclovir with respect to efficacy in preventing vision loss. To compare a treatment regimen that incorporates highly active local therapy (ganciclovir device) with a treatment regimen that does not.

Timeline

Start
1997-05
Primary completion
2000-06
Completion
2000-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CIDOFOVIR ANHYDROUS Small molecule 5 mg/kg Intravenous